世界の糖尿病性腎症市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV11633)
◆英語タイトル:Global Diabetic Nephropathy Market Size, Status and Forecast 2020-2026
◆商品コード:QYR20NV11633
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:98
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは糖尿病性腎症の世界市場について調査・分析した資料です。種類別(ACE阻害薬、ARB、利尿薬、カルシウムチャネル遮断薬(CCB)、レニン阻害薬、結合組織成長因子(CTGF)阻害薬、抗酸化炎症調節薬(AIM)、単球化学誘引物質タンパク質(MCP)阻害薬、エンドセリンA受容体(ETAR)拮抗薬Gタンパク質共役型受容体(GPCR))の市場規模、用途別(病院、がん研究所、診断研究所)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別糖尿病性腎症の競争状況、市場シェア
・世界の糖尿病性腎症市場:種類別市場規模 2015年-2020年(ACE阻害薬、ARB、利尿薬、カルシウムチャネル遮断薬(CCB)、レニン阻害薬、結合組織成長因子(CTGF)阻害薬、抗酸化炎症調節薬(AIM)、単球化学誘引物質タンパク質(MCP)阻害薬、エンドセリンA受容体(ETAR)拮抗薬Gタンパク質共役型受容体(GPCR))
・世界の糖尿病性腎症市場:種類別市場規模予測 2021年-2026年(ACE阻害薬、ARB、利尿薬、カルシウムチャネル遮断薬(CCB)、レニン阻害薬、結合組織成長因子(CTGF)阻害薬、抗酸化炎症調節薬(AIM)、単球化学誘引物質タンパク質(MCP)阻害薬、エンドセリンA受容体(ETAR)拮抗薬Gタンパク質共役型受容体(GPCR))
・世界の糖尿病性腎症市場:用途別市場規模 2015年-2020年(病院、がん研究所、診断研究所)
・世界の糖尿病性腎症市場:用途別市場規模予測 2021年-2026年(病院、がん研究所、診断研究所)
・北米の糖尿病性腎症市場分析:米国、カナダ
・ヨーロッパの糖尿病性腎症市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの糖尿病性腎症市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の糖尿病性腎症市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの糖尿病性腎症市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Novartis、Merck、Pfizer、Abbott Laboratories、Sanofi、Eli Lilly、AbbVie、Reata Pharmaceuticals、Bayer、Mitsubishi Tanabe Pharma
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market.
North America has the largest market for the global diabetic nephropathy market. However, In terms of growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic nephropathy.

Market Analysis and Insights: Global Diabetic Nephropathy Market
The global Diabetic Nephropathy market size is projected to reach US$ 2522.4 million by 2026, from US$ 2398.5 million in 2020, at a CAGR of 4.8%% during 2021-2026.

Global Diabetic Nephropathy Scope and Market Size
Diabetic Nephropathy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Diabetic Nephropathy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Novartis
Merck
Pfizer
Abbott Laboratories
Sanofi
Eli Lilly
AbbVie
Reata Pharmaceuticals
Bayer
Mitsubishi Tanabe Pharma

Market segment by Type, the product can be split into
ACE Inhibitors
ARBs
Diuretics
Calcium Channel Blockers(CCBs)
Renin Inhibitors
Connective Tissue Growth Factor (CTGF) Inhibitors
Antioxidant Inflammation Modulators(AIMs)
Monocyte Chemoattractant Protein (MCP)Inhibitors
Endothelin-A Receptor(ETAR)Antagonist
G Protein-Coupled Receptors (GPCRs)
Market segment by Application, split into
Hospitals
Cancer Research Institutes
Diagnostic Labs

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Diabetic Nephropathy Revenue
1.4 Market by Type
1.4.1 Global Diabetic Nephropathy Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 ACE Inhibitors
1.4.3 ARBs
1.4.4 Diuretics
1.4.5 Calcium Channel Blockers(CCBs)
1.4.6 Renin Inhibitors
1.4.7 Connective Tissue Growth Factor (CTGF) Inhibitors
1.4.8 Antioxidant Inflammation Modulators(AIMs)
1.4.9 Monocyte Chemoattractant Protein (MCP)Inhibitors
1.4.10 Endothelin-A Receptor(ETAR)Antagonist
1.4.11 G Protein-Coupled Receptors (GPCRs)
1.5 Market by Application
1.5.1 Global Diabetic Nephropathy Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Cancer Research Institutes
1.5.4 Diagnostic Labs
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Diabetic Nephropathy Market Perspective (2015-2026)
2.2 Global Diabetic Nephropathy Growth Trends by Regions
2.2.1 Diabetic Nephropathy Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Diabetic Nephropathy Historic Market Share by Regions (2015-2020)
2.2.3 Diabetic Nephropathy Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Diabetic Nephropathy Market Growth Strategy
2.3.6 Primary Interviews with Key Diabetic Nephropathy Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Diabetic Nephropathy Players by Market Size
3.1.1 Global Top Diabetic Nephropathy Players by Revenue (2015-2020)
3.1.2 Global Diabetic Nephropathy Revenue Market Share by Players (2015-2020)
3.1.3 Global Diabetic Nephropathy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Diabetic Nephropathy Market Concentration Ratio
3.2.1 Global Diabetic Nephropathy Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Diabetic Nephropathy Revenue in 2019
3.3 Diabetic Nephropathy Key Players Head office and Area Served
3.4 Key Players Diabetic Nephropathy Product Solution and Service
3.5 Date of Enter into Diabetic Nephropathy Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Diabetic Nephropathy Historic Market Size by Type (2015-2020)
4.2 Global Diabetic Nephropathy Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Diabetic Nephropathy Market Size by Application (2015-2020)
5.2 Global Diabetic Nephropathy Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Diabetic Nephropathy Market Size (2015-2020)
6.2 Diabetic Nephropathy Key Players in North America (2019-2020)
6.3 North America Diabetic Nephropathy Market Size by Type (2015-2020)
6.4 North America Diabetic Nephropathy Market Size by Application (2015-2020)

7 Europe
7.1 Europe Diabetic Nephropathy Market Size (2015-2020)
7.2 Diabetic Nephropathy Key Players in Europe (2019-2020)
7.3 Europe Diabetic Nephropathy Market Size by Type (2015-2020)
7.4 Europe Diabetic Nephropathy Market Size by Application (2015-2020)

8 China
8.1 China Diabetic Nephropathy Market Size (2015-2020)
8.2 Diabetic Nephropathy Key Players in China (2019-2020)
8.3 China Diabetic Nephropathy Market Size by Type (2015-2020)
8.4 China Diabetic Nephropathy Market Size by Application (2015-2020)

9 Japan
9.1 Japan Diabetic Nephropathy Market Size (2015-2020)
9.2 Diabetic Nephropathy Key Players in Japan (2019-2020)
9.3 Japan Diabetic Nephropathy Market Size by Type (2015-2020)
9.4 Japan Diabetic Nephropathy Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Diabetic Nephropathy Market Size (2015-2020)
10.2 Diabetic Nephropathy Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Diabetic Nephropathy Market Size by Type (2015-2020)
10.4 Southeast Asia Diabetic Nephropathy Market Size by Application (2015-2020)

11 India
11.1 India Diabetic Nephropathy Market Size (2015-2020)
11.2 Diabetic Nephropathy Key Players in India (2019-2020)
11.3 India Diabetic Nephropathy Market Size by Type (2015-2020)
11.4 India Diabetic Nephropathy Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Diabetic Nephropathy Market Size (2015-2020)
12.2 Diabetic Nephropathy Key Players in Central & South America (2019-2020)
12.3 Central & South America Diabetic Nephropathy Market Size by Type (2015-2020)
12.4 Central & South America Diabetic Nephropathy Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Novartis
13.1.1 Novartis Company Details
13.1.2 Novartis Business Overview
13.1.3 Novartis Diabetic Nephropathy Introduction
13.1.4 Novartis Revenue in Diabetic Nephropathy Business (2015-2020))
13.1.5 Novartis Recent Development
13.2 Merck
13.2.1 Merck Company Details
13.2.2 Merck Business Overview
13.2.3 Merck Diabetic Nephropathy Introduction
13.2.4 Merck Revenue in Diabetic Nephropathy Business (2015-2020)
13.2.5 Merck Recent Development
13.3 Pfizer
13.3.1 Pfizer Company Details
13.3.2 Pfizer Business Overview
13.3.3 Pfizer Diabetic Nephropathy Introduction
13.3.4 Pfizer Revenue in Diabetic Nephropathy Business (2015-2020)
13.3.5 Pfizer Recent Development
13.4 Abbott Laboratories
13.4.1 Abbott Laboratories Company Details
13.4.2 Abbott Laboratories Business Overview
13.4.3 Abbott Laboratories Diabetic Nephropathy Introduction
13.4.4 Abbott Laboratories Revenue in Diabetic Nephropathy Business (2015-2020)
13.4.5 Abbott Laboratories Recent Development
13.5 Sanofi
13.5.1 Sanofi Company Details
13.5.2 Sanofi Business Overview
13.5.3 Sanofi Diabetic Nephropathy Introduction
13.5.4 Sanofi Revenue in Diabetic Nephropathy Business (2015-2020)
13.5.5 Sanofi Recent Development
13.6 Eli Lilly
13.6.1 Eli Lilly Company Details
13.6.2 Eli Lilly Business Overview
13.6.3 Eli Lilly Diabetic Nephropathy Introduction
13.6.4 Eli Lilly Revenue in Diabetic Nephropathy Business (2015-2020)
13.6.5 Eli Lilly Recent Development
13.7 AbbVie
13.7.1 AbbVie Company Details
13.7.2 AbbVie Business Overview
13.7.3 AbbVie Diabetic Nephropathy Introduction
13.7.4 AbbVie Revenue in Diabetic Nephropathy Business (2015-2020)
13.7.5 AbbVie Recent Development
13.8 Reata Pharmaceuticals
13.8.1 Reata Pharmaceuticals Company Details
13.8.2 Reata Pharmaceuticals Business Overview
13.8.3 Reata Pharmaceuticals Diabetic Nephropathy Introduction
13.8.4 Reata Pharmaceuticals Revenue in Diabetic Nephropathy Business (2015-2020)
13.8.5 Reata Pharmaceuticals Recent Development
13.9 Bayer
13.9.1 Bayer Company Details
13.9.2 Bayer Business Overview
13.9.3 Bayer Diabetic Nephropathy Introduction
13.9.4 Bayer Revenue in Diabetic Nephropathy Business (2015-2020)
13.9.5 Bayer Recent Development
13.10 Mitsubishi Tanabe Pharma
13.10.1 Mitsubishi Tanabe Pharma Company Details
13.10.2 Mitsubishi Tanabe Pharma Business Overview
13.10.3 Mitsubishi Tanabe Pharma Diabetic Nephropathy Introduction
13.10.4 Mitsubishi Tanabe Pharma Revenue in Diabetic Nephropathy Business (2015-2020)
13.10.5 Mitsubishi Tanabe Pharma Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

...

【掲載企業】

Novartis、Merck、Pfizer、Abbott Laboratories、Sanofi、Eli Lilly、AbbVie、Reata Pharmaceuticals、Bayer、Mitsubishi Tanabe Pharma

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の糖尿病性腎症市場2026:インサイト・予測(Global Diabetic Nephropathy Market Size, Status and Forecast 2020-2026)]についてメールでお問い合わせはこちらでお願いします。